Gentamicin Dosing in Neonates with Normal Renal Function: Trough and Peak Levels

Autor:	Kristin, O'Connor, Mark W, Davies, Pieter, Koorts, David W, Cartwright, Karen, Whitfield
Rok vydání:	2021
Předmět:	Male Dose-Response Relationship Drug Infant Newborn Gestational Age Kidney Function Tests Drug Administration Schedule Anti-Bacterial Agents Cohort Studies Humans Administration Intravenous Female Prospective Studies Drug Monitoring Gentamicins Follow-Up Studies
Zdroj:	European journal of drug metabolism and pharmacokinetics. 46(5)
ISSN:	2107-0180
Popis:	BACKGROUND AND OBJECTIVE: Gentamicin is commonly used in neonates, and it requires drug concentration monitoring. The objective of this study was to determine the extent of high trough (≥ 2 mg/l) and therapeutic peak serum gentamicin concentrations (5-12 mg/l) using our current gentamicin regimen and to adjust the dosing regimen accordingly and reassess.This was a prospective cohort study of neonates, with normal renal function, who were prescribed gentamicin. Group 1: March 2014-July 2017-gentamicin intravenous (IV) 2.5 mg/kg given every 36 h if30 weeks gestational age (GA) and every 24 h if ≥ 30 weeks GA; Group 2: August 2019-February 2020-gentamicin IV 3.5 mg/kg given every 36 h if30 weeks GA and every 24 h if ≥ 30 weeks GA. We assessed the number of neonates with aberrant trough and peak serum gentamicin concentrations.Forty-eight neonates30 weeks GA and 34 ≥ 30 weeks GA were given 2.5 mg/kg gentamicin. Eleven (23%) neonates30 weeks GA and four (13%) ≥ 30 weeks GA had subtherapeutic peak concentrations (5 mg/l); none had supratherapeutic (12 mg/l) or toxic trough concentrations (≥ 2 mg/l). Forty-four neonates30 weeks GA and 54 ≥ 30 weeks GA were given 3.5 mg/kg gentamicin. Eighty-four (86%) had non-toxic trough concentrations (2 mg/l). One (1%)30 weeks GA neonate had subtherapeutic (5 mg/l) and one (1%) neonate ≥ 30 weeks GA had supratherapeutic (12 mg/l) peak concentrations.Gentamicin regimen of 2.5 mg/kg given every 36 h for neonates30 weeks GA and every 24 h for neonates ≥ 30 weeks GA was suboptimal at achieving therapeutic gentamicin peak. Increasing the dosage to 3.5 mg/kg achieved therapeutic peak concentrations in 98% and non-toxic trough concentrations in 86% of all neonates (prior to dose interval adjustment).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::19bc8ec8a0b21a27dcb12c4925d6dce9 https://pubmed.ncbi.nlm.nih.gov/34370216 Zobrazit plný text záznamu Full text from SpringerLink